| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System | ||
Phase 3 topline data readout example | Phase 3 | — | Subscribe to access the data. | Small Molecules | Cardiovascular System |
Recent Updates
Recently added Catalysts
Tenax Therapeutics, Inc.$17.55
-0.77 (-4.2%)
C 41Pipeline Score Fair Value Pharma · Clinical
Market Cap
321.75 M
EPS
-1.40
P/E Ratio
-
Value Trade
6.08 M
SEC Financials
Q1 2026Dilution Risk
Revenue
-
R&D Expenses
11.54 M
Operating CF
-9.31 M
Total Assets
123.18 M
Total Liabilities
8.49 M
Equity
114.69 M
D/E Ratio
12,345
3.32 %
Week
-11.46 %
1 Month
-2.57 %
3 Month
55.71 %
6 Month
-99.61 %
5 Year
-100 %
All Time
Cash Data
Cash Position
118.80 M
Monthly Burn
3.10 M
Runway
36.6 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
1.05 M
52 Week Range
5.34 - 18.38
% held by Insiders
9.26 %
% held by Institutions
67.5 %
Enterprise Value
203.00 M
Total Shares
6.24 M
Short %
31.97 %
Float Shares
5.59 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Tenax Therapeutics, Inc.
247Total events
5Upcoming
30Tier-1 (high impact)
2009 – 2027Coverage
Upcoming catalysts 5
2026-H1
T2Enrollment Complete
Enrollment completion of 230 patients in Phase 3 LEVEL study expected in first half of 2026
Event history 242
Q3 2026
◆Topline ReadoutTNX-103Clinical Data
Topline data from LEVEL expected in second half of 2026
pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF)source ↗
Jun 2026
◆Topline ReadoutTNX-103Clinical Data
Topline data expected middle of 2026 from LEVEL study
PH-HFpEFsource ↗
May 12, 2026
▲Management ChangeCorporate
Appointments of Thomas Staab as CFO and Timothy Healey as Chief Commercial Officer
May 11, 2026
May 4, 2026
Q2 2026
Mar 2026
▲Enrollment CompleteTNX-103Trial
Completed randomization of more than 230 patients in Phase 3 LEVEL study
PH-HFpEFsource ↗
Mar 10, 2026
◆Oral PresentationPresentation
Fireside chat at 2026 Leerink Partners Global Healthcare Conference
Mar 2026
▲Enrollment CompleteTNX-103Trial
Enrollment completed for LEVEL trial
pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF)source ↗
Drug Pipeline Intelligence
C41
Pipeline Score $446M
Pipeline ValueFair Value
Valuation Signal2
Drugs Scored1.4x
rNPV / MCap Top 58%
Micro Cap (rank 384 of 911)
Percentile RankTenax Therapeutics, Inc. carries a moderate pipeline score (41/100), with $1.1B risk-adjusted pipeline value, led by TNX-103 in Pulmonary Hypertension Associated With HFpEF (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TNX-103 Small molecule | Pulmonary Hypertension | Phase 3 | NCT05983250 | 43% | $742M | RECRUITING | 230 | STALLED | B (70) | Oct 1, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TNX-103 | pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) | Phase 3 | 2025-12-18 | powered at well over 90% to detect a 25 meter change in 6-minute walk distance (6MWD); result of less than the assumed 55 meters Read More | Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment Read More | |
TNX-103 | pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) | Phase 3 | 2025-12-18 | powered at well over 90% to detect a 25 meter change in 6-minute walk distance (6MWD); result of less than the assumed 55 meters Read More | Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment Read More | |
TNX-103 | pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) | Phase 3 | 2025-12-18 | powered at well over 90% to detect a 25 meter change in 6-minute walk distance (6MWD); result of less than the assumed 55 meters Read More | Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in TENX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
TENX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
TENX▲ +16.3%on this news· ran to +33% by day 3
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Tenax Therapeutics announced that results from its Phase 3 LEVEL clinical trial will be presented at the ESC Congress 2026. The company expects to report topline results in August 2026, following a successful enrollment of over 230 patients. The trial evaluates TNX-103 in patients with pulmonary hypertension due to heart failure with preserved ejection fraction.
Read more →TENXTenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical t
Tenax Therapeutics, Inc. reported its financial results for Q1 2026, highlighting progress in its Phase 3 LEVEL study of TNX-103, with topline data expected to be released in Q3 2026. The company is enhancing its leadership team and reports a strong cash position of $118.8 million, expected to fund operations through the first quarter of 2028. Despite an increased net loss and rising R&D expenses, Tenax remains committed to advancing its cardiopulmonary therapies.
Read more →TENXTenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Tenax Therapeutics announced the awarding of inducement stock options to four new non-executive employees as part of their employment package. The options, totaling 657,500 shares, will vest over time and were approved by the Board's Compensation Committee. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's commitment to enhancing its clinical operations and product development.
Read more →TENXTenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer
Tenax Therapeutics has appointed Timothy Healey as Chief Commercial Officer, effective immediately. Healey brings a wealth of experience in drug launches and commercialization strategies, aiming to prepare Tenax and its product TNX-103 for market success. His previous roles include leadership positions at Eversana and Lantheus, emphasizing his capability in the pharmaceutical sector.
Read more →TENXTenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer Mr. Staab has over 25 years of financial and executive experience across the healthcare industry
Tenax Therapeutics has appointed Thomas R. Staab, II as the new Chief Financial Officer, effective May 11, 2026. Mr. Staab brings over 25 years of experience in financial leadership within the healthcare industry and succeeds Thomas McGauley, who served as interim CFO since December 2024. His appointment comes at a pivotal time for Tenax as the company expands its global registrational program and advances its development of levosimendan for treating PH-HFpEF patients.
Read more →TENX▲ +31.7%on this news
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Achieved randomization target of 230 patients in LEVEL study, topline data expected in third quarter of 2026 In
Tenax Therapeutics reported its financial results for Q4 and the full year of 2025, highlighting that it has reached its target of randomizing 230 patients in the Phase 3 LEVEL study. The company also initiated the global Phase 3 LEVEL-2 trial for its drug TNX-103, which aims to address pulmonary hypertension in heart failure with preserved ejection fraction. Despite significant progress, the company reported a net loss of $52.6 million for 2025, alongside rising expenses in research and development.
Read more →TENXTenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference
Tenax Therapeutics will participate in the 2026 Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, FL. The company's executives, including the CEO and CMO, will engage in a fireside chat on March 10, 2026. This event aims to showcase Tenax's advancements in cardiopulmonary therapies, particularly for pulmonary hypertension.
Read more →TENXTenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026
Tenax Therapeutics will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026, scheduled for February 11-12, 2026, in New York. The company's President and Chief Executive Officer, Chris Giordano, along with Chief Business Officer Douglas Randall, will engage in a fireside chat. This event presents an opportunity for Tenax to highlight its development-stage cardiopulmonary therapies.
Read more →TENX▲ +8.7%on this news
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Tenax Therapeutics announced that the prespecified Blinded Sample Size Re-estimation for its LEVEL study shows it is adequately powered to detect significant changes in the primary endpoint. The company confirmed that enrollment is on track to complete in the first half of 2026, with topline data expected later that year. Additionally, Tenax has initiated the LEVEL-2 study, further advancing its clinical program for TNX-103 in treating pulmonary hypertension.
Read more →TENXTenax Therapeutics to Participate in Upcoming Investor Conferences
Tenax Therapeutics, a development-stage pharmaceutical company, will present at two investor conferences in December 2025. The conferences include the 8th Annual Evercore Healthcare Conference and the Piper Sandler 37th Annual Healthcare Conference, where key executives will participate in fireside chats. The company is focused on developing novel therapies for cardiopulmonary conditions and holds global rights to the drug levosimendan, targeting pulmonary hypertension with no approved treatments currently available.
Read more →TENXTenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected i
Tenax Therapeutics reported its financial results for Q3 2025 alongside updates on its clinical programs. The company is advancing the Phase 3 LEVEL study for its lead product TNX-103 in patients suffering from pulmonary hypertension with preserved ejection fraction (PH-HFpEF), with plans to complete enrollment of 230 patients in the first half of 2026. Additionally, Tenax is preparing to initiate a second Phase 3 study, LEVEL-2, later this year. Financially, Tenax reported a net loss of $15.8 million for the quarter, significantly higher than in the same period in the previous year.
Read more →TENXTenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF
Tenax Therapeutics is set to host a virtual KOL call on November 13, 2025, to discuss TNX-103, an oral formulation of levosimendan, aimed at treating pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). The call will feature notable experts in cardiovascular medicine and will provide insights into the treatment landscape and the ongoing Phase 3 studies: LEVEL and LEVEL-2. The company is optimistic about the outcomes as enrollment continues in the North American LEVEL study, with the global LEVEL-2 study expected to initiate in 2025.
Read more →TENXTenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Tenax Therapeutics, a Phase 3 development-stage pharmaceutical company, announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference, scheduled for November 10-12, 2025, in Boston. The presentation will feature CEO Chris Giordano and CMO Stuart Rich in a fireside chat format. This event highlights Tenax's focus on developing cardiopulmonary therapies, particularly its work on levosimendan for treating pulmonary hypertension.
Read more →TENXTenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF Provides Patent Protection in Europe Through at Least December 2040 Further IP Protection for TNX-103
Tenax Therapeutics announced that the European Patent Office intends to grant a patent for the use of levosimendan in treating pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). This patent will grant intellectual property protection in Europe until at least December 2040, potentially extending beyond that. The decision supports Tenax's development of TNX-103 and other formulations of levosimendan, as the company prepares for its Phase 3 study, LEVEL-2, aimed at gaining regulatory approval for its treatment.
Read more →TENXTenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
Tenax Therapeutics, Inc. will participate in the Cantor Global Healthcare Conference 2025 held in New York from September 3-5, 2025. The fireside chat featuring CEO Chris Giordano and CMO Stuart Rich, M.D., is scheduled for September 4 at 10:20 a.m. ET. This event will allow the company to share insights about its development-stage treatments, particularly for cardiopulmonary therapies. Tenax is known for its work on levosimendan, which aims to address pulmonary hypertension.
Read more →TENXTenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Phase 3 LEVEL Study Ongoing, Enrollment Completion (230 Patients) Expected in First Half of 2026, with Topline Data Expected
Tenax Therapeutics has reported its financial results for the second quarter of 2025, indicating significant progress in its clinical development efforts. The ongoing Phase 3 LEVEL study of TNX-103 is expected to complete enrollment of 230 patients in the first half of 2026, while plans for a second Phase 3 study (LEVEL-2) are on track for initiation this year. Despite reporting a net loss of $10.9 million, the company maintains a robust cash position, anticipated to fund operations until 2027. Recent advancements include the publication of a LEVEL protocol design paper and positive updates regarding patent applications.
Read more →TENXTenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle o
Tenax Therapeutics released its financial results for the first quarter of 2025 and provided updates on its corporate activities. The company expects to complete enrollment for its Phase 3 LEVEL study of TNX-103 by the end of 2025, with topline data anticipated in mid-2026. Additionally, Tenax plans to initiate a second Phase 3 study, LEVEL-2, later this year. Despite a reported net loss of $10.4 million in Q1, the company maintains a strong cash position of $111.4 million.
Read more →TENXTenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Tenax Therapeutics, Inc. will present at the 24th Annual Needham Virtual Healthcare Conference from April 7-10, 2025. The corporate presentation is scheduled for April 7 at 3:45 p.m. ET and will feature key executives including the CEO and CMO. The event offers Tenax an opportunity to showcase its innovative cardiopulmonary therapies, particularly the development of levosimendan for treating PH-HFpEF. The live and archived webcast will be accessible through the company's investor relations webpage.
Read more →TENXTenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Suppor
Tenax Therapeutics reported its fourth quarter and full year 2024 financial results, highlighting significant fundraising successes and advancements in its clinical trials. The company raised approximately $125 million through private placements to support the development of its drug candidate TNX-103. Tenax is expanding its Phase 3 LEVEL study and anticipates completing enrollment by the end of 2025, with topline data expected in mid-2026. However, they also reported increased net losses and rising R&D expenses associated with their ongoing studies.
Read more →TENXTenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Tenax Therapeutics has received FDA approval to expand its Phase 3 LEVEL study for TNX-103 (oral levosimendan) and initiate a second global trial, LEVEL-2. The expansion increases patient enrollment from 152 to 230, enhancing the statistical power to over 95%. Patient retention in the LEVEL study has been promising, with over 95% adhering to the treatment. The dual Phase 3 studies are expected to provide critical safety data for marketing authorization applications in the U.S. and other regions.
Read more →TENXTenax Therapeutics Announces $25 Million Private Placement
Tenax Therapeutics has announced a $25 million private placement agreement with RTW Investments, aimed at supporting its clinical developments. The private placement involves the issuance of shares and pre-funded warrants, expected to close on March 5, 2025. The proceeds will primarily be used for advancing Phase 3 clinical trials, as well as for general corporate purposes. The offering is subject to customary closing conditions and has not been registered under the Securities Act, raising potential regulatory considerations.
Read more →TENXTenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
Tenax Therapeutics, Inc. announced its upcoming participation in the Leerink Partners 2025 Global Healthcare Conference, scheduled for March 10-12, 2025, in Miami, FL. The company's President and CEO, Chris Giordano, along with Chief Medical Officer Stuart Rich, will participate in a fireside chat. This event highlights Tenax's focus on developing products for cardiovascular and pulmonary diseases. The live presentation can be accessed via the company's investor relations webpage.
Read more →TENXTenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Tenax Therapeutics, a Phase 3 pharmaceutical company, announced its participation in the Guggenheim SMID Cap Biotech Conference on February 5-6, 2025. The company will engage in a fireside chat and hold one-on-one meetings with investors. Tenax is focused on developing products for cardiovascular and pulmonary diseases, including levosimendan.
Read more →TENXTenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
Tenax Therapeutics has appointed Gillian Andor as Vice President of Clinical Operations. With over 20 years of experience, Andor will lead the Clinical Operations function, supporting the ongoing Phase 3 LEVEL study for oral levosimendan in treating pulmonary hypertension. Her expertise is expected to accelerate the company's clinical development and regulatory preparations.
Read more →TENXTenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics reported strong financial results for Q3 2024, raising $100 million in a private placement. The company is actively enrolling patients in its Phase 3 LEVEL study, which aims to evaluate levosimendan for treating pulmonary hypertension with heart failure. Despite a net loss of $4 million, Tenax has sufficient cash to support operations through 2027.
Read more →TENXTenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Tenax Therapeutics, a Phase 3 pharmaceutical company, will present at the Guggenheim Healthcare Innovation Conference in Boston from November 11-13, 2024. CEO Chris Giordano is scheduled to discuss the company's progress, particularly regarding levosimendan. Investors can attend the session live or via webcast, with details available on the company's investor relations webpage.
Read more →TENX▲ +11.6%on this news
Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors
Tenax Therapeutics reported its financial results for the second quarter of 2024, highlighting a significant capital raise of approximately $100 million through private placement. The company continues to enroll patients in its Phase 3 LEVEL study, focusing on the treatment of pulmonary hypertension with preserved ejection fraction (PH-HFpEF). Additionally, Tenax secured important intellectual property rights for levosimendan and conducted a KOL event to discuss unmet medical needs in heart failure. Despite a net loss of $3.6 million, the company's ongoing developments indicate a commitment to addressing high unmet medical needs in cardiovascular health.
Read more →TENX▼ -10.9%on this newsshared move
Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program
Tenax Therapeutics has successfully closed a $100 million private placement to advance its oral levosimendan Phase 3 development program. The funding will support the ongoing LEVEL study and initiate a second Phase 3 study planned for 2025. This financing reflects strong investor confidence in levosimendan's potential to improve outcomes for patients with pulmonary hypertension due to heart failure with preserved ejection fraction.
Read more →TENX▲ +28.8%on this news
Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement
Tenax Therapeutics announced an oversubscribed private placement expected to raise approximately $100 million. The financing, led by BVF Partners LP, will support ongoing clinical trials, including the Phase 3 LEVEL trial for levosimendan. The placement is set to close on August 8, 2024, pending customary conditions.
Read more →TENXTenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Com
Tenax Therapeutics has reported its financial results for the first quarter of 2024 and provided updates on its Phase 3 LEVEL Study for TNX-103 (oral levosimendan) targeting PH-HFpEF. Patient enrollment is ongoing in the study, which includes 24 investigative sites. The company has secured global commercial rights for levosimendan and received a new U.S. patent to strengthen its intellectual property position. However, Tenax reported a net loss of $3.8 million for the quarter, showing an increase in financial challenges as research and development costs rise.
Read more →TENX▲ +6.3%on this news
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Tenax Therapeutics announced the granting of a new U.S. patent for levosimendan, covering its use in treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). The patent includes protections for various administration methods and combinations with other cardiovascular drugs. This development is part of Tenax's strategy to address unmet medical needs in cardiovascular medicine.
Read more →TENXTenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study”
Tenax Therapeutics is hosting a KOL event to discuss the potential of levosimendan in treating pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). The event will feature expert cardiologists who will explore the disease's pathophysiology and the ongoing Phase 3 LEVEL Study. Attendees will receive updates on the study and have the opportunity to engage in a Q&A session.
Read more →TENX▲ +9.6%on this news
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmon
Tenax Therapeutics has announced significant advancements in its clinical development and business strategy, highlighted by the first patient enrollment in the Phase 3 LEVEL study evaluating TNX-103 for pulmonary hypertension associated with heart failure. The company has expanded its U.S. intellectual property rights for levosimendan, which may enhance its commercial prospects. With a recent public offering raising approximately $8 million, Tenax is set to further support its clinical initiatives. Despite the positive trajectory, the company reported a net loss in 2023, reflecting ongoing financial challenges.
Read more →TENXTenax Therapeutics to Present at the 36th Annual Roth Conference
Tenax Therapeutics, Inc. will participate in the 36th Annual Roth Conference from March 17-19, 2024. CEO Chris Giordano is scheduled to present an update on the company's development of levosimendan during a fireside chat on March 18. In addition, the company will hold one-on-one investor meetings, offering opportunities for deeper discussions about its products and pipeline.
Read more →TENX▲ +10.9%on this news· ran to +21% by day 1
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024
Tenax Therapeutics has announced that Dr. Sanjiv Shah will present data on levosimendan for treating pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) at the THT 2024 conference in Boston. The presentation is scheduled for March 6, 2024, highlighting the drug's potential benefits for patients. Tenax is currently conducting the Phase 3 LEVEL study, which investigates levosimendan's efficacy and safety in this patient population. The presentation will draw attention from international heart failure experts, underscoring the ongoing innovation in heart failure treatment.
Read more →TENXTenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan Amendment to existing exclusive license agreement with Orion Corporation expands Tenax's territory rights from North
Tenax Therapeutics has announced a global license amendment with Orion Corporation, expanding its rights to levosimendan from North America to worldwide. This strategic move includes improved royalty terms and modified milestone provisions, particularly an additional payment upon regulatory approval in Japan. The expansion positions Tenax to establish potential global partnerships and enhance shareholder value as it advances levosimendan into Phase 3 testing for pulmonary hypertension with heart failure with preserved ejection fraction. However, the amendment excludes neurological indications from the company's commercialization rights, presenting a limitation to their market strategy.
Read more →TENX▼ -64.4%on this news
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
Tenax Therapeutics, Inc. announced the pricing of its public offering, which aims to raise approximately $9 million by selling 1,600,000 shares and warrants for a common stock exercise. Proceeds will be used primarily to support the LEVEL trial, a Phase 3 study of their cardiac treatment levosimendan, as well as for general corporate purposes. The offering is set to close around February 12, 2024, pending the satisfaction of customary closing conditions. Roth Capital Partners is serving as the exclusive placement agent for the offering.
Read more →TENX▲ +24.5%on this news· ran to -58% by day 3shared move
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) Over 40 site
Tenax Therapeutics has successfully enrolled the first patient in its Phase 3 LEVEL study evaluating TNX-103 (oral levosimendan) for treating pulmonary hypertension in patients with heart failure and preserved ejection fraction (PH-HFpEF). Conducted across over 40 sites in the U.S. and Canada, the trial aims to gather data on 152 patients, with topline results expected in the second half of 2025. This study marks a pivotal step as no drugs have been approved by the FDA for PH-HFpEF to date, potentially positioning TNX-103 as a groundbreaking therapy in this area.
Read more →TENX▲ +31.3%on this newsshared move
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejecti
Tenax Therapeutics announced that the USPTO has issued a Notice of Allowance for its patent application concerning levosimendan's use in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF). This patent will extend U.S. intellectual property protection until December 2040 and covers multiple dosing routes and combinations with cardiovascular drugs. This is the third patent issued to the company since March 2023, highlighting its commitment to innovative treatments for cardiovascular diseases. The news comes alongside the initiation of Tenax's Phase 3 LEVEL study, which will further investigate the efficacy of levosimendan in improving exercise performance in affected patients.
Read more →TENX▼ -16.8%on this news· ran to -47% by day 3
Tenax Therapeutics Announces Reverse Stock Split
Tenax Therapeutics, Inc. has announced a reverse stock split of its common stock at a 1-for-80 ratio, effective January 2, 2024. This action, approved by stockholders, is intended to ensure compliance with Nasdaq's minimum bid price requirement. As a result of the split, the number of outstanding shares will drop significantly, affecting all shareholders uniformly. The adjustment will also include changes to the exercise prices of stock options and warrants, although the number of authorized shares will remain unchanged.
Read more →TENX▼ -9.2%on this news· ran to -22% by day 3
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board
Tenax Therapeutics has announced the appointment of Dr. Javed Butler to its PH-HFpEF Scientific Advisory Board. Dr. Butler, a highly respected clinical trialist in cardiovascular medicine, brings extensive experience to the board alongside other notable cardiovascular leaders. The company also received FDA clearance to proceed with a Phase 3 trial for oral levosimendan, which is currently considered to have potential benefits for patients suffering from pulmonary hypertension with heart failure with preserved ejection fraction.
Read more →TENX▲ +297.4%on this news
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites ex
Tenax Therapeutics has received FDA clearance for their Investigational New Drug application for TNX-103, an oral formulation of levosimendan, intended for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This decision enables the initiation of the first Phase 3 study, termed the LEVEL Study, expected to begin in the fourth quarter of 2023. Notably, the FDA did not require a long-term cardiovascular outcomes trial for the drug, which could streamline the development process. The approval comes amidst a landscape where no FDA-approved therapies for PH-HFpEF currently exist, highlighting a significant unmet medical need.
Read more →TENX▲ +10.4%on this news
Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) New U.S. patent provides intellectual property (IP) protection until De
Tenax Therapeutics announced the issuance of a U.S. patent for oral levosimendan targeting pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF), set to expire in December 2040. This patent enhances its intellectual property portfolio in a market lacking approved treatments, with an estimated potential to generate substantial sales. The company aims to begin a Phase 3 trial for TNX-103 in 2023, seeking to demonstrate its efficacy in a significant patient population. As highlighted by executives, this development addresses a critical unmet medical need.
Read more →TENX▲ +13.3%on this news
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection
Tenax Therapeutics has achieved a major milestone with the U.S. Patent and Trademark Office granting a Notice of Allowance for its patent application covering the use of oral levosimendan (TNX-103) in treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This patent, expected to be granted by December 2040, will significantly bolster Tenax's intellectual property protection in a market with over 1.6 million affected patients in North America. As there are currently no FDA-approved treatments for this condition, the company aims to progress its oral formulation into Phase 3 trials in 2023, positioning it as a potential pioneer therapy in this high unmet medical need area.
Read more →TENXTenax Therapeutics Provides 2023 Business Update
Tenax Therapeutics has announced a strategic decision to prioritize the clinical development of TNX-103 (oral levosimendan) for treating pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). This decision is driven by the significant unmet medical need and the absence of FDA-approved therapies for this condition. The company is set to initiate a Phase 3 trial for TNX-103 in 2023, capitalizing on an expanding intellectual property estate. Despite the positive developments, the timeline for a related Phase 3 trial of imatinib has been pushed beyond 2023 due to financial considerations.
Read more →TENXTenax Therapeutics Provides 2023 Business Update Company to prioritize the clinical development of TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension and heart failure with preserved ejection fractio
Tenax Therapeutics has announced a business update focusing on the clinical development of TNX-103 (oral levosimendan) for pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF). The decision to prioritize this therapy follows a review indicating a significant unmet medical need, as there are currently no FDA-approved treatments for this condition. The company plans to initiate Phase 3 trials in 2023, aiming to address a considerable patient population. Additionally, Tenax's growing intellectual property portfolio supports their development efforts and potential market entry.
Read more →TENX▼ -5.4%on this news· ran to -20% by day 3
Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) Patent provides intellectual property protection until Dece
Tenax Therapeutics has announced the issuance of a U.S. patent for IV levosimendan aimed at treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF). This patent strengthens the company’s intellectual property portfolio, which is crucial as it faces no existing FDA-approved treatments for this condition. The patent is effective until December 2040, enabling Tenax to explore various opportunities to advance levosimendan through clinical development and potential partnerships. Positive results from prior studies suggest that levosimendan may significantly improve exercise tolerance for patients suffering from PH-HFpEF, marking a potential breakthrough in treatment.
Read more →TENX▼ -20.8%on this news· ran to -40% by day 3
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
Tenax Therapeutics, Inc. has announced the pricing of a public offering aimed at generating approximately $15.6 million. This will involve the issuance of shares and warrants, with proceeds designated for advancing the clinical development of treatments such as imatinib for pulmonary arterial hypertension and levosimendan for heart failure. The company's objectives include launching Phase 3 trials and securing regulatory approvals for these promising therapies, which are expected to address high unmet medical needs in their respective areas.
Read more →TENX▼ -20.3%on this newsshared move
Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) Patent is expected to provide addition
Tenax Therapeutics has received a Notice of Allowance from the USPTO for its patent application regarding the use of IV levosimendan for treating PH-HFpEF. This patent protection, effective until 2040, enhances Tenax's intellectual property portfolio for a therapy addressing a condition currently without FDA-approved treatments. The patent is grounded in evidence from the HELP Study, which demonstrated significant improvements in exercise capacity for patients. The company aims to proceed with further development steps, as the FDA has validated important clinical endpoints.
Read more →TENXTenax Therapeutics Announces Reverse Stock Split MORRISVILLE, NC
Tenax Therapeutics, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective January 4, 2023. The decision follows approval by stockholders and aims to meet Nasdaq's minimum bid price requirements. The reverse split will reduce the number of outstanding shares while not altering stockholder ownership percentages significantly. The company continues to focus on its development of products for cardiovascular and pulmonary diseases.
Read more →TENXPositive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) MORRISVILLE, N.C.
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) MORRISVILLE, N.C. October 10, 2022 (GLOBE NEWSWIRE) - Tenax Therapeutics, Inc. (Nasdaq:
Read more →TENXTenax Therapeutics Announces the Evaluation of Strategic Alternatives MORRISVILLE, N.C.
tenx_ex991.htm EXHIBIT 99.1 Tenax Therapeutics Announces the Evaluation of Strategic Alternatives MORRISVILLE, N.C., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commerciali
Read more →TENXTenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension TNX-201 (oral imatinib modified release tablets) Formulation Development has been
tenx_ex991.htm EXHIBIT 99.1 Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension TNX-201 (oral imatinib modified release tablets) Formulation Development has been Successfully Completed Manu
Read more →TENXTenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules Morrisville, NC
PRESS RELEASE, DATED MAY 18, 2022 tenx_ex991.htm EXHIBIT 99.1 Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules Morrisville, NC, May 18, 2022 - Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on i
Read more →TENXTenax Therapeutics Appoints Robyn Hunter to the Board of Directors Morrisville, NC
tenx_ex991.htm EXHIBIT 99.1 Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors Morrisville, NC - January 31, 2022 -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that
Read more →TENXTENAX THERAPEUTICS January 2022 I Corporate Presentation www.tenaxthera.com NASDAQ TENX Disclaimer Except for historical information, all the statements, expectations and assumptions contained in this presentation are fo
tenx_ex991.htm EXHIBIT 99.1 TENAX THERAPEUTICS January 2022 I Corporate Presentation www.tenaxthera.com NASDAQ TENX Disclaimer Except for historical information, all the statements, expectations and assumptions contained in this presentation are forward-looking statements. Actu
Read more →TENXTenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102) Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Excl
tenx_ex991.htm EXHIBIT 99.1 Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102) Provides Broad Coverage for Use of TNX-102 for the Treatment of Human Subjects with Any Health Condition Patent Term to 2039, Exclusive of Any Possible Exten
Read more →TENXTenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan) Successfully Completes IV to Oral Tran
PRESS RELEASE DATED JANUARY 4, 2022 tenx_ex991.htm EXHIBIT 99.1 Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs Receives a Notice of Allowance of Multiple Patent Claims for TNX-102 (subcutaneous levosimendan) Successfully Completes IV to
Read more →TENXTenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules – Anthony DiTonno Retires from Tenax; Christopher Giordano Appointed as CEO – Morrisville, N
Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules Anthony DiTonno Retires from Tenax; Christopher Giordano Appointed as CEO Morrisville, NC, July 7, 2021 Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pha
Read more →TENXTenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders Morrisville, NC –
Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Morrisville, NC April 7, 2021 Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutic
Read more →TENXTenax Therapeutics, Inc. Expands Board of Directors ● New Board appointments strengthen Tenax with world-class expertise in cardiovascular drug development, commercial strategy, and business development ● N
Tenax Therapeutics, Inc. Expands Board of Directors New Board appointments strengthen Tenax with world-class expertise in cardiovascular drug development, commercial strategy, and business development New Directors will provide significant guidance as Tenax is poised to adva
Read more →TENXTenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med ● Expands pipeline into Pulmonary Arterial Hypertension (PAH), a progressive, fatal orphan disease without a cure ● Imatinib
Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Expands pipeline into Pulmonary Arterial Hypertension (PAH), a progressive, fatal orphan disease without a cure Imatinib, a tyrosine kinase inhibitor (TKI), has been shown to block critical disease promoting
Read more →TENXTenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation ● Tenax gains developmental and commercial rights for a fully-developed oral levosimend
Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Tenax gains developmental and commercial rights for a fully-developed oral levosimendan formulation in the U.S. and Oral formulation expected to be used in upcomi
Read more →TENXTenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD Morrisville, NC –
Therapeutics Expands Board of Directors with the of Two New Directors, Steven Boyd and Keith Maher, MD Morrisville, NC July 20, 2020 -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products
Read more →TENXTenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules Morrisville, NC
Tenax Therapeutics Announces $8.0 Million Registered Direct and Priced At-the-Market Under Nasdaq Rules Morrisville, NC, July 6, 2020 Tenax Therapeutics, Inc. (Nasdaq: TENX) ( Tenax or the Company ), a specialty pharmaceutical company focused on identifying, developing, and
Read more →TENXTenax Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) – Demonstrated a significant red
Therapeutics Reports Positive Results from Phase 2 Trial of Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) Demonstrated a significant reduction in right atrial and pulmonary capillary wedge pressures Demonst
Read more →TENXTenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market Morrisville, NC
Tenax Therapeutics Announces $2.75 Million Registered Direct Offering Priced At-the-Market Morrisville, NC, March 12, 2020 Tenax Therapeutics, Inc. (Nasdaq: TENX) ( Tenax or the Company ), a specialty pharmaceutical company focused on identifying, developing and commercializ
Read more →TENXTenax Therapeutics Announces Closing of $10 Million Underwritten Offering Morrisville, NC
Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering Morrisville, NC, December 11, 2018 Tenax Therapeutics, Inc. (Nasdaq: TENX) ( Tenax or the Company ), a specialty pharmaceutical company focused on identifying, developing and commercializing products f
Read more →TENXTenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO Morrisville, NC
Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO Morrisville, NC, June 5, 2018 Tenax Therapeutics, Inc. (Nasdaq: TENX) ("Tenax" or the "Company"), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the
Read more →TENXTenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Morrisville, NC
Tenax Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement Morrisville, NC, March 14, 2018 - Tenax Therapeutics, TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today ann
Read more →TENXTenax Therapeutics Announces Reverse Stock Split Morrisville, NC
Tenax Therapeutics Announces Reverse Stock Split Morrisville, NC, February 23, 2018 - Tenax Therapeutics, TENX), a specialty pharmaceutical company focused on providing products to address conditions with significant unmet medical needs, today announced a reverse stock split
Read more →TENXTenax Therapeutics Provides Regulatory Update on Levosimendan Morrisville, NC
Tenax Therapeutics Provides Regulatory Update on Morrisville, NC, July 28, 2017 Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today provides a regulator
Read more →TENXTenax Therapeutics Announces Review of Strategic Alternatives and Business Update – Ladenburg Thalmann Engaged to Assist in the Process – – John Kelley Resigns as CEO; Michael Jebsen, President and C
Tenax Therapeutics Announces Review of Strategic Alternatives and Ladenburg Thalmann Engaged to Assist in the Process John Kelley Resigns as CEO; Michael Jebsen, President and CFO, Appointed as Interim CEO Morrisville, NC, April 5, 2017 Tenax Therapeutics, Inc. (NASDAQ: TENX
Read more →TENXTenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery – Study Did Not Achieve Statistically Significant Reductions in Dual or Quad Primary Endpoints – – Study M
Tenax Therapeutics Announces Top-Line Results From Phase 3 LEVO-CTS Trial in Cardiac Surgery Study Did Not Achieve Statistically Significant Reductions in Dual or Quad Primary Study Met Two Secondary Endpoints with Statistically Significant Reduction in Incidence of LCOS and
Read more →TENXTenax Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update – DSMB recommends continuation of Phase 3 LEVO-CTS trial in cardiac surgery following interim analysis from first 451
Tenax Therapeutics Announces First Quarter 2016 Financial Results and Provides Corporate Update DSMB recommends continuation of Phase 3 LEVO-CTS trial in cardiac surgery following interim analysis from first 451 patients LEVO-CTS enrollment rate remains on track, with top-line
Read more →TENXTenax Therapeutics Provides Clinical and Corporate Update - Hosted Analyst Day on April 13 with levosimendan clinical and development experts - - Provided enrollment progress update for ongoing LEVO-CTS and LeoPARDS tria
Tenax Therapeutics Provides Clinical and Corporate Update - Hosted Analyst Day on April 13 with levosimendan clinical and development experts - - Provided enrollment progress update for ongoing LEVO-CTS and LeoPARDS trials - - Announced change in fiscal year end - Morrisville
Read more →TENXOxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results - Acquired strategic assets from Phyxius Pharma, including lead candidate levosimendan; named John Kelley as CEO - - Activated sites for Phase 3 LEVO-CT
Oxygen Biotherapeutics Announces Fiscal Year 2014 Financial Results Morrisville, NC, July 29, 2014 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, tod
Read more →TENXOxygen Biotherapeutics Inc., Announces the Appointment of Industry Veteran Gerald Proehl to its Board of Directors Morrisville, NC
Oxygen Biotherapeutics Inc., Announces the Appointment of Industry Veteran Gerald Proehl to its Board of Directors Morrisville, NC, April 4, 2014 - Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfo
Read more →TENXOxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program Morrisville, NC
Oxygen Biotherapeutics Inc. Provides an Update on Communication with the FDA Regarding Oxycyte Development Program Morrisville, NC, March 3, 2014 - Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfo
Read more →TENXOxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimendan; John Kelley Appointed CEO of Oxygen Biotherapeutics MORRISVILLE, NC
Oxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimendan; John Kelley Appointed CEO of Oxygen Biotherapeutics MORRISVILLE, NC, November 14, 2013 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a developer of oxygen-carrying therapeutics, toda
Read more →TENXOxygen Biotherapeutics Receives $6 Million in Net Proceeds from Warrant Exercises MORRISVILLE, NC
Oxygen Biotherapeutics Receives $6 Million in Net Proceeds from Warrant Exercises MORRISVILLE, NC, November 08, 2013 - Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT) a developer of oxygen-carrying therapeutics, today announced the Company has received approximately $6 million thro
Read more →TENXOxygen Biotherapeutics Prices Public Offering with Gross Proceeds of $5.4 million MORRISVILLE, NC
Oxygen Biotherapeutics Prices Public Offering with Gross Proceeds of $5.4 million MORRISVILLE, NC, July 22, 2013 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced the pricing of a public offering and the entry into definitive agreements with investors for the sale o
Read more →TENXEllen Corliss SVP, Investor Relations & Corporate Communications Oxygen Biotherapeutics, Inc. (919) 855-2112 Oxygen Biotherapeutics Receives Favorable NASDAQ Listing Decision MORRISVILLE, N.C.
SVP, Investor Relations & Corporate Communications Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics Receives Favorable NASDAQ Listing Decision MORRISVILLE, N.C. May 16, 2013 -- Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), today announced that the NASDAQ Listing Qualificati
Read more →TENXEllen Corliss SVP, Investor Relations & Corporate Communications Oxygen Biotherapeutics, Inc. (919) 855-2112 Oxygen Biotherapeutics Announces 20:1 Reverse Stock Split Effective After Market Close on May 10 th MO
SVP, Investor Relations & Corporate Communications Oxygen Biotherapeutics, Inc. Oxygen Biotherapeutics Announces 20:1 Reverse Stock Split Effective After Market Close on May 10th MORRISVILLE, NC, May 10, 2013 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), today announced the
Read more →TENXOXYGEN BIOTHERAPEUTICS, INC. (a development stage enterprise) STATEMENTS OF OPERATIONS unaudited) Period from
Senior Vice President Corporate Communications & Investor Relations Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2013 MORRISVILLE, NC, March 18, 2013 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a development stage biomedical company focused on
Read more →TENXEllen Corliss Corporate Communications & Investor Relations (919) 855-2112 Oxygen Biotherapeutics Enters Into Definitive Agreements for Financing for up to $2.1 million in Gross Proceeds MORRISVILLE, NC
Corporate Communications & Investor Relations Oxygen Biotherapeutics Enters Into Definitive Agreements for Financing for up to $2.1 million in Gross Proceeds MORRISVILLE, NC, February 22, 2013 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) today announced that it has entered i
Read more →TENXEllen Corliss SVP, Investor Relations & Corporate Communications (919) 855-2112 Oxygen Biotherapeutics Enters License and Supply Agreement for Dermacyte Products with the Cosmetics Division of Valor
SVP, Investor Relations & Corporate Communications Oxygen Biotherapeutics Enters License and Supply Agreement for Dermacyte Products with the Cosmetics Division of Valor SA MORRISVILLE, NC, February 11, 2013 - Oxygen Biotherapeutics, Inc. ("OBI") (NASDAQ: OXBT), announced toda
Read more →TENXEllen Corliss Vice President Corporate Communications & Investor Relations (919) 855-2112 Oxygen Biotherapeutics Reports Second Quarter FY2013 Financial Results -Management to host teleconference to discuss fina
Corporate Communications & Investor Relations Oxygen Biotherapeutics Reports Second Quarter FY2013 Financial Results -Management to host teleconference to discuss financial results on December 17- MORRISVILLE, NC, December 17, 2012 - Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT)
Read more →TENXEllen Corliss SVP, Investor Relations & Corporate Communications (919) 855-2112 Oxygen Biotherapeutics Reports First Quarter FY2013 Financial Results -Conference Call and Webcast for Shareholders set for Septemb
SVP, Investor Relations & Corporate Communications Oxygen Biotherapeutics Reports First Quarter FY2013 Financial Results -Conference Call and Webcast for Shareholders set for September 21st- MORRISVILLE, NC, September 19, 2012 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a
Read more →TENXEllen Corliss Vice President Corporate Communications & Investor Relations (919) 855-2112 Oxygen Biotherapeutics Relocating R&D Function to North Carolina from California MORRISVILLE, NC
Corporate Communications & Investor Relations Oxygen Biotherapeutics Relocating R&D Function to North Carolina from California MORRISVILLE, NC, August 28, 2012 - Oxygen Biotherapeutics, Inc. ("OBI") (NASDAQ: OXBT) announced today that it is searching for laboratory space in t
Read more →TENXEllen Corliss Senior Vice President Corporate Communications &Investor Relations (919)855-2112 Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2012 MORRISVILLE, NC
Senior Vice President Corporate Communications Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2012 MORRISVILLE, NC, July 24, 2012 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a development stage biomedical company focused on developing oxygen-carrying intra
Read more →TENXThe securities described above were offered by the Company pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). A prospectus supplement relat
SVP, Corporate Communications & Investor Relations Oxygen Biotherapeutics Announces Expected Closing on Second Installment of December 2011 Financing and Amends Agreement to Allow for a Third Tranche Later This Year Pending Shareholder Approval MORRISVILLE, NC, June 15, 2012 -
Read more →TENXEllen Corliss Senior Vice President Corporate Communications & Investor Relations (919) 855-2112 Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2012 MORRISVILLE, NC
Senior Vice President Corporate Communications & Investor Relations Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2012 MORRISVILLE, NC, March 15, 2012 - Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), a development stage biomedical company focused on
Read more →TENXEllen Corliss Vice President Corporate Communications & Investor Relations (919) 855-2112 Oxygen Biotherapeutics Reports Second Quarter FY2012 Financial Results -Management to host teleconference to discuss fina
Corporate Communications & Investor Relations Oxygen Biotherapeutics Reports Second Quarter FY2012 Financial Results -Management to host teleconference to discuss financial results on December 19- MORRISVILLE, NC, December 16, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ and S
Read more →TENXEllen Corliss Corporate Communications & Investor Relations (919) 855-2112 Oxygen Biotherapeutics Announces Registered Financing for up to $7.5 million in Gross Proceeds MORRISVILLE, NC
Corporate Communications & Investor Relations Oxygen Biotherapeutics Announces Registered Financing for up to $7.5 million in Gross Proceeds MORRISVILLE, NC, December 9, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ & SIX Swiss Exchange: OXBT) today announced that it has entere
Read more →TENXRene A. Eckert C/O Oxygen Biotherapeutics, Inc. ONE Copley Parkway, Suite 490 Morrisville, North Carolina 27560
Oxygen Biotherapeutics, Inc. ONE Copley Parkway, Suite 490 Morrisville, North Carolina 27560 Members of the Board of Directors: I hereby resign from my position as a member of the Board of Directors of Oxygen Biotherapeutics, Inc. (the "Company"), effective as of today. I ha
Read more →TENXEllen Corliss Corporate Communications & Investor Relations (919) 855-2112 Oxygen Biotherapeutics Reports First Quarter FY2012 Financial Results and Announces Conference Call and Webcast for Shareholders MORRISV
Corporate Communications & Investor Relations Oxygen Biotherapeutics Reports First Quarter FY2012 Financial Results and Announces Conference Call and Webcast for Shareholders MORRISVILLE, NC, September 19, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXB
Read more →TENXI am very surprised at this. I don't agree and do not accept my termination, and I request this filing be stopped until the attorneys have talked. And then it needs to be changed. Chris Stern
I am very surprised at this. I don't agree and do not accept my termination, and I request this filing be stopped until the attorneys have talked. And then it needs to be changed.
Read more →TENXOxygen Biotherapeutics Ellen Corliss Vice President, Corporate Communications & Investor Relations (919) 855-2112 Oxygen Biotherapeutics Announces Dismissal of Chris J. Stern as CEO and Appointments of Michael
Oxygen Biotherapeutics Corporate Communications & Investor Relations Oxygen Biotherapeutics Announces Dismissal of Chris J. Stern as CEO and Appointments of Michael B. Jebsen as Interim CEO and Rene Eckert as Interim Chairman -Oxygen Biotherapeutics to reschedule its 2011 G
Read more →TENXEllen Corliss Vice President Corporate Communications & Investor Relations (919) 855-2112 Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2011 MORRISVILLE, NC
Corporate Communications & Investor Relations Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2011 MORRISVILLE, NC, July 14, 2011 - Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT), a development stage biomedical company focused on developing
Read more →TENXOxygen Biotherapeutics, Inc. Announces Registered Direct Offering of $5 million in Common Stock and Warrants DURHAM, N.C.
Oxygen Biotherapeutics, Inc. Announces Registered Direct Offering of $5 million in Common Stock and Warrants DURHAM, N.C., May 4, 2010 Oxygen Biotherapeutics, Inc., a Delaware corporation (NASDAQ: OXBT) (the Company ), announced today that it entered into purchase agreements wi
Read more →TENXOXYGEN BIOTHERAPEUTICS CHAIRMAN'S BLOG March 2010 Blog In this Blog I want to briefly update our TBI Trial and address our 8K filing this week regarding changes in the size and composition of our Board of Directors. Our
In this Blog I want to briefly update our TBI Trial and address our 8K filing this week regarding changes in the size and composition of our Board of Directors. Our TBI trial is moving ahead as planned. This past week, the Israeli portion of the trial enrolled and treated the fi
Read more →TENXIn this Blog I want to briefly address the recurring question about updates on our patient enrollment in the TBI trial. I have said before and will say again, that we will not be providing any kind of patient enrollment
In this Blog I want to briefly address the recurring question about updates on our patient enrollment in the TBI trial. I have said before and will say again, that we will not be providing any kind of patient enrollment tally or trial results prior to completion of treatment and
Read more →TENXBusiness Update
Dear Shareholders and Friends: As we head into a new year, I would like to update you on our most recent business developments. Why consumer, non-clinical? These topical treatments may be able to qualify for registration as medical devices, which would have a shorter and simpl
Read more →TENXThe Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward looking information made on the Company s behalf. All statements other than statements of historical facts which address the Company
Navy Secure IP across all core and non core therapeutic areas. Raise more money and make money to generate capital sufficient to generate proof of principal data in all three clinical areas. Selectively partner for products or sell indications US/CA Escalation Study Oxycyte Big P
Read more →TENXSynthetic Blood 8K Press Release for Bob Larsen Synthetic Blood International, Inc. Announces Passing of Interim CEO Robert Larsen CONTACT: Abe Wischnia, Abe Wischnia & Associates 619-795-2345 COSTA MESA, Calif.--(BUSINE
International, Inc. Announces Passing of Interim CEO Robert Larsen Abe Wischnia & Associates COSTA MESA, Calif.--(BUSINESS WIRE)--March 24, 2008 Synthetic Blood International, Inc. (OTCBB:SYBD) today announced the death Sunday night of interim CEO Robert Larsen. He was 79.
Read more →TENXSynthetic Blood Press Release 11/20/2007 Company Contact: Synthetic Blood International, Inc. Joan Mahan 800-809-6054 For Immediate Release Synthetic Blood Announces Major Restructuring Receives $1 million advance agains
Synthetic Blood International, Inc. Joan Synthetic Blood Announces Major Restructuring Receives $1 million advance against $12 million convertible note Announces management and board changes COSTA MESA, Calif. (November 20, 2007) Synthetic Blood International, Inc. (OTC/BB:
Read more →Competitive Position
How TENX ranks across every disease it competes inCompetitive Position is a premium feature
See how TENX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial